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Summary
This measure establishes “California Institute for Regenerative
Medicine” to regulate and fund stem cell research, constitutional
right to conduct such research, and oversight committee.
Prohibits funding of human reproductive cloning research.
Fiscal Impact: State cost of about $6 billion over 30 years to pay
off both the principal ($3 billion) and interest ($3 billion) on
the bonds. State payments averaging about $200 million per
year.
What Your Vote Means
BALLOT MEASURE SUMMARY
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Summary
A “Yes” vote approves, and a “No” vote rejects legislation requir-
ing health care coverage for employees, as specified, working
for large and medium employers. Fiscal Impact: Significant
expenditures fully offset, mainly by employer fees, for a state
program primarily to purchase private health insurance cover-
age.  Significant county health program savings. Significant
public employer health coverage costs. Significant net state rev-
enue losses. Overall unknown net state and local savings or
costs.
What Your Vote Means
Arguments
Pro
Prop. 72 keeps private health
coverage within reach of work-
ing families. It requires large
and mid-sized companies to
pay for private coverage, caps
employee share of premiums,
and sets coverage standards.
Doctors, nurses, and consumers
agree: With premiums rising
and employees losing health
insurance, Prop. 72 provides
needed protection.
Con
Proposition 72 creates a govern-
ment-run healthcare scheme
funded by an estimated 
$7 billion in new taxes on em-
ployers and workers by 2007.
You could get forced from your
existing plan into the govern-
ment system and lose access to
your doctors and hospitals.
Educators, charities, taxpayers,
doctors say “NO on 72.”
Stem Cell Research. Funding. 
Bonds. Initiative Constitutional 
Amendment and Statute.
Arguments
Yes
A YES vote on this measure
means: The state would estab-
lish a new state medical
research institute and author-
ize the issuance of $3 billion in
state general obligation bonds
to provide funding for stem
cell research and research facil-
ities in California.
No 
A NO vote on this measure
means: Funding for stem cell
research in California would
depend upon actions by the
Legislature and Governor and
other entities which provide
research funding.
Pro
71 authorizes stem cell research
to find new CURES FOR CAN-
CER, HEART DISEASE, DIA-
BETES, and many other dis-
eases, SAVE MILLIONS OF
LIVES, and CUT HEALTH
CARE COSTS BY BILLIONS.
And, 71 prohibits cloning to
create babies. Join non-profit
disease organizations, Nobel
Prize scientists, doctors, and
nurses: Vote YES on 71.
Con
Adds $3 billion of bond debt
to California’s massive debt
load. Money would fund
huge, new bureaucracy to pro-
mote human embryo cloning.
Few controls, no real account-
ability for how money is spent.
Exempts new bureaucracy
from aspects of “open meet-
ing” laws. Opposed by
women’s groups, leading doc-
tors, and medical ethicists.
For
YES on 71: Coalition for Stem
Cell Research and Cures
11271 Ventura Blvd.
Studio City, CA 91604
800-931-CURE (2873)
info@YESon71.com
www.YESon71.com
Against
Doctors, Patients, and
Taxpayers for Fiscal
Responsibility
P.O. Box 2402
Covina, CA 91722
www.NoOn71.com
Health Care Coverage Requirements.
Referendum.
For Additional Information
Yes
A YES vote on this measure
means: Certain employers would
be required to provide health
coverage for their employees
and in some cases dependents
through either (1) paying a fee
to a new state program primari-
ly to purchase private health
insurance coverage or (2)
arranging directly with health
insurance providers for health
care coverage. The state would
also establish a new program to
assist lower-income employees
to pay their share of health
care premiums.
No 
A NO vote on this measure
means: The state would continue
to allow employers to choose
whether to provide health
insurance for their employees
and dependents. The state
would not establish a new pro-
gram to provide assistance to
low-income employees in pay-
ing premiums for health care
coverage at their workplace.
For
Anthony Wright
Health Access
1127 11th Street
Sacramento, CA 95814
916-442-2308
awright@health-access.org
www.YesonProp72.com
Against
Californians Against
Government Run
Healthcare
1201 K Street, Suite 1100
Sacramento, CA 95814-3938
info@noprop72.org
www.noprop72.org
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Stem Cell Research. Funding. Bonds.
Initiative Constitutional Amendment and Statute.
• Establishes “California Institute for Regenerative Medicine” to regulate stem cell research and
provide funding, through grants and loans, for such research and research facilities.
• Establishes constitutional right to conduct stem cell research; prohibits Institute’s funding of
human reproductive cloning research.
• Establishes oversight committee to govern Institute.
• Provides General Fund loan up to $3 million for Institute’s initial administration/implementation
costs.
• Authorizes issuance of general obligation bonds to finance Institute activities up to $3 billion
subject to annual limit of $350 million.
• Appropriates monies from General Fund to pay for bonds.
Summary of Legislative Analyst’s Estimate of Net State and Local Government 
Fiscal Impact:
• State cost of about $6 billion over 30 years to pay off both the principal ($3 billion) and 
interest ($3 billion) on the bonds. Payments averaging about $200 million per year.
• Unknown potential state and local revenue gains and cost savings to the extent that the
research projects funded by this measure result in additional economic activity and reduced
public health care costs.
BACKGROUND
Stem Cell Research. A stem cell is a type of cell
found in both animals and humans that has the
potential to develop into many different types of
specialized cells in the body. Scientists have con-
ducted research on stem cells to better understand
how animals and humans develop and how healthy
cells replace damaged cells. This research has led
to the development of treatments of a variety of
cancers and blood disorders. Some scientists
believe that stem cell research may, at some point
in the future, result in new treatments of diseases.
(See the nearby box for additional information on
stem cell research.)
California law currently permits research involv-
ing stem cells. The University of California (UC) is
currently engaged in this type of research. The
exact amount of UC research funding devoted to
stem cell research could not be determined, but the
available information suggests that the total funds
spent for these purposes range from the millions of
dollars to the tens of millions of dollars annually.
The federal government provides funding for
research that uses different types of stem cells,
including adult and embryonic stem cells. In the
2002 federal fiscal year, the federal government
dedicated more than $180 million in funding for
stem cell research conducted nationwide. The fed-
eral government currently places certain restric-
tions on funding for research that uses embryonic
stem cells.
State law currently prohibits human reproduc-
tive cloning, a process to create a human that is an
exact genetic copy of another.
General Obligation Bonds. The state generally
uses general obligation bond funds to finance
major state capital outlay projects. General obliga-
tion bonds are backed by the state, meaning that
ANALYSIS BY THE LEGISLATIVE ANALYST
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OFFICIAL TITLE AND SUMMARY Prepared by the Attorney General
ANALYSIS BY THE LEGISLATIVE ANALYST (CONT.)
the state guarantees payment of the principal and
interest costs on these bonds. General Fund revenues
are used to pay these costs. These revenues come
primarily from the state personal and corporate
income taxes and the sales tax. For more informa-
tion regarding general obligation bonds, please
refer to the section of the ballot pamphlet entitled
“An Overview of State Bond Debt.”
Analysis | 69For text of Proposition 71 see page 147.
PROPOSAL
The measure authorizes the state to sell $3 bil-
lion in general obligation bonds to provide fund-
ing for stem cell research and research facilities in
California. A new state medical research institute
would be established to use the bond funds to
award grants and loans for stem cell research and
research facilities, and to manage stem cell
research activities funded by this measure within
California. The major provisions of the measure
are discussed below.
New State Institute Created. This measure would
establish the California Institute for Regenerative
Medicine to award grants and loans for stem cell
research and research facilities. The institute
would also be responsible for establishing regula-
tory standards for stem cell research funded by the
grants and loans and managing such research and
the development of related facilities. The institute
could have a staff of up to 50 employees who,
under the measure, would be exempt from state
civil service requirements.
The institute would be governed by a 29-mem-
ber Independent Citizen’s Oversight Committee
(ICOC), comprised of representatives of specified
UC campuses, another public or private California
university, nonprofit academic and medical
research institutions, companies with expertise in
developing medical therapies, and disease
research advocacy groups. The Governor,
Lieutenant Governor, Treasurer, Controller,
Speaker of the Assembly, President pro Tempore
of the Senate, and certain UC campus Chancellors
would make the appointments to the ICOC.
General Obligation Bond Funding. The measure
would authorize the state to sell $3 billion in gen-
eral obligation bonds, and limit bond sales to no
more than $350 million per year. The measure
states its intent, but does not require in statute,
that the bonds be sold during a ten-year period.
For at least the first five years after the measure
took effect, the repayment of the principal would
be postponed and the interest on the debt would
be repaid using bond proceeds rather than the
STEM CELL RESEARCH. FUNDING. BONDS.
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STEM CELLS AND STEM CELL RESEARCH
What Are Stem Cells? As described by the National
Institutes of Health, stem cells differ from other cells 
in three main ways. First, they are “unspecialized,”
meaning they do not perform specialized functions,
such as the way heart muscle cells help blood flow or
red blood cells carry oxygen through the bloodstream.
Second, under certain conditions, they can be
transformed into cells with specialized functions. Third,
these cells are capable of reproducing themselves over
an extended period of time. As a result, these cells can
serve as a repair system for the body by replenishing
other cells for as long as the person or animal is alive.
What Are Embryonic and Adult Stem Cells? Human
embryonic stem cells appear in an embryo, a fertilized
human egg, five to seven days after conception. They
are ordinarily extracted from extra embryos that have
been donated for research by parents who tried to
conceive a child through certain procedures performed
at fertility clinics. Embryonic stem cells have the
potential to develop into all cell types of the body.
Adult stem cells are obtained for scientific research
from many organs and tissues including the brain,
bone marrow, blood vessels, skin, and the liver. These
stem cells are generally limited to becoming the cell
type of its tissue of origin.
Why Do Researchers Want to Study Stem Cells? Scientists
indicate that there are many ways in which human 
stem cells can be used in basic and clinical research.
Stem cell research may provide information on the
complex events that occur during human development
that lead to serious medical conditions like cancer and
birth defects. Human stem cells could be used to test
the safety of drugs. Also, researchers indicate that stem
cells offer the possibility of a renewable source of
replacement cells and tissues to treat diseases such as
Parkinson’s, Alzheimer’s, heart disease, or diabetes, or
to treat spinal cord injuries.
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General Fund. Subsequent interest and principal
payments after that five-year period would come
from the General Fund. The proceeds from the
bond sales would be placed in a new California
Stem Cell Research and Cures Fund and used pri-
marily to fund the various activities of the insti-
tute. The funds authorized for the institute would
be continuously appropriated without regard to
fiscal year.
Once the measure took effect, the institute
would receive a $3 million start-up loan from the
state General Fund for initial administrative and
implementation costs. The institute would later
repay the General Fund loan using the proceeds
from the sale of bonds authorized under this 
measure.
How Funding Would Be Spent. Under the meas-
ure, any funding needed for various bond-related
costs (for example, the cost of administering the
bond sales) would be deducted before bond pro-
ceeds were spent for other purposes.
The institute would be able to use up to 3 per-
cent of the remaining bond proceeds for general
administrative costs and up to an additional 3 per-
cent for administrative costs associated with grant-
making activities. The remaining funds would be
used for the grants and loans for research and
research facilities.
Priority for research grant funding would be
given to stem cell research that met the institute’s
criteria and was unlikely to receive federal funding.
In some cases, funding could also be provided for
other types of research that were determined to
cure or provide new types of treatment of diseases
and injuries. The institute would not be allowed to
fund research on human reproductive cloning.
Up to 10 percent of the funds available for
grants and loans could be used to develop scien-
tific and medical research facilities for nonprofit
entities within the first five years of the implemen-
tation of the measure.
Benefits From Royalties and Patents. The ICOC
would establish standards requiring that all grants
and loans be subject to agreements allowing the
state to financially benefit from patents, royalties,
and licenses resulting from the research activities
funded under the measure.
Right to Conduct Stem Cell Research. Consistent
with current statute, this measure would make
conducting stem cell research a state constitu-
tional right.
FISCAL EFFECTS
Borrowing Costs. As noted earlier, this measure
provides that no General Fund payments for the
bonds would occur in the first five years after it
took effect. The costs to the state after that would
depend on the interest rates obtained when the
bonds were sold and the length of time it took to
repay the debt. If the $3 billion in bonds author-
ized by this measure were repaid over a 30-year
period at an average interest rate of 5.25 percent,
the cost to the General Fund would be approxi-
mately $6 billion to pay off both the principal 
($3 billion) and interest ($3 billion). The average
payment for principal and interest would be
approximately $200 million per year. 
ANALYSIS BY THE LEGISLATIVE ANALYST (CONT.)
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Institute Operating Costs. As noted earlier, this
measure would limit the amount of bond funding
available that the institute could use for its admin-
istrative activities. The measure does not specify
what would happen if the institute’s administrative
costs were greater than the amount of available
bond funding. The amount of additional General
Fund support that would be required, if any, is
unknown, but would be unlikely to exceed a few
million dollars annually.
Loan Repayment Revenues. If the institute awards
loans in addition to grants for stem cell research
and facilities, the institute would eventually receive
revenues from the repayment of those loans. The
measure specifies that any such loan repayment
revenues would be used either to provide 
additional grants and loans or to pay ongoing costs
for the administration of the bonds.
State Revenues From Research. As noted earlier, this
measure would allow the state to receive payments
from patents, royalties, and licenses resulting from
the research funded by the institute. The amount of
revenues the state would receive from those types of
arrangements is unknown but could be significant.
The amount of revenue from this source would
depend on the nature of the research funded by the
institute and the exact terms of any agreements for
sharing of revenues resulting from that research.
Effects on University System. To the extent that the
UC system receives a share of the grants awarded by
the institute, it could attract additional federal or
private research funding for this same purpose.
The UC system could also eventually receive signif-
icant revenues from patents, royalties, and licenses.
Other Potential Fiscal Effects. If the measure were
to result in economic and other benefits that would
not otherwise have occurred, it could produce
unknown indirect state and local revenue gains
and cost savings. Such effects could result, for
example, if the added research activity and associ-
ated investments due to the measure generate net
gains in jobs and taxable income, or if funded proj-
ects reduce the costs of health care to government
employees and recipients of state services. The like-
lihood and magnitude of these and other potential
indirect fiscal effects are unknown.
REBUTTAL to Argument in Favor of Proposition 71
Stem Cell Research? YES! Human Embryo Cloning? NO!
Here are just some of the many problems with
Proposition 71:
** It specifically supports “embryo cloning” research—
also called “somatic cell nuclear transfer”—which poses
risks to women and unique ethical problems. To pro-
vide scientists with eggs for embryo cloning, at least ini-
tially, thousands of women may be subjected to the sub-
stantial risks of high dose hormones and egg extraction
procedures just for the purposes of research. In addi-
tion, the perfection of embryo cloning technology—
even if initially for medical therapies only—will
increase the likelihood that human clones will be pro-
duced.
** Why privilege this research over other important
research and medical needs, especially given the limits
on how much California can invest? Why not issue
bonds for programs that ALREADY have proven their
cost effectiveness? Embryo stem cell research in nonhu-
man animals has produced only limited results. More
compelling evidence of its efficacy should be required
before a large commitment of public resources to study
it in humans.
** Proponents are manipulating those seeking cures,
building false hopes with exaggerated claims, and cre-
ating a costly program without adequate oversight or
accountability.
Stem cell research should be supported, but not this way.
And don’t be fooled by those who say that the opponents of
Proposition 71 are all opposed to abortion and embryo
stem cell research. Many of us are pro-choice, do not
oppose all embryo stem cell research, and still oppose this
initiative.
Vote “No” on Proposition 71.
JUDY NORSIGIAN, Executive Director 
Our Bodies Ourselves
FRANCINE COEYTAUX, Founder
Pacific Institute for Women’s Health
TINA STEVENS, Ph.D., Author
Bioethics in America: Origins and Cultural Politics
PROPOSITION 71 IS ABOUT CURING DISEASES AND
SAVING LIVES.
Stem cells are unique cells that generate healthy new
cells, tissues, and organs. Medical researchers believe stem
cell research could lead to treatments and cures for many
diseases and injuries, including:
Cancer, heart disease, diabetes, Alzheimer’s, Parkinson’s,
HIV/AIDS, multiple sclerosis, lung diseases, and spinal
injuries.
In fact, medical problems that could benefit from stem cell research
affect 128 million Americans—including a child or adult in nearly
half of all California families.
71 CLOSES THE RESEARCH GAP.
Unfortunately, political squabbling has severely limited
funding for the most promising areas of stem cell research.
Meanwhile, millions of people are suffering and dying.
Prop. 71, the California Stem Cell Research and Cures
Initiative, is an affordable solution that closes the research
gap, so new treatments and cures can be found.
That’s why a YES vote on 71 is endorsed by a broad coali-
tion that includes OVER 20 NOBEL PRIZE WINNING SCI-
ENTISTS, doctors, nurses, Democrats, Republicans, and
dozens of organizations, including:
• Alzheimer’s Association, California Council • American
Nurses Association of California • California Medical
Association (representing 35,000 doctors) • Cancer
Research and Prevention Foundation • Christopher Reeve
Paralysis Foundation • Cystic Fibrosis Research, Inc. 
• Elizabeth Glaser Pediatric AIDS Foundation • Juvenile
Diabetes Research Foundation • Michael J. Fox Foundation
for Parkinson’s Research • Prostate Cancer Foundation 
• Sickle Cell Disease Foundation of California.
71 PROTECTS CALIFORNIA’S TAXPAYERS AND BUDGET.
Prop. 71 doesn’t create or increase any taxes.
It authorizes tax-free state bonds that will provide a maxi-
mum of $350 million per year over ten years to support stem
cell research at California universities, medical schools, hos-
pitals, and research facilities.
• These bonds are self-financing during the first five years,
so there’s no cost to the State’s General Fund during this
period of economic recovery.
• By making California a leader in stem cell research and
giving our State an opportunity to share in royalties from
the research, 71 will generate thousands of new jobs and
millions in new state revenues.
That’s why California’s Chief Financial Officers, State 
Controller Steve Westly and State Treasurer Phil Angelides, endorse
Prop. 71.
STRICT FINANCIAL AND ETHICAL CONTROLS.
Research grants will be allocated by an Independent
Citizen’s Oversight Committee, guided by medical experts,
representatives of disease groups, and financial experts—
and subject to independent audits, public hearings, and
annual public reports.
Prop. 71 also prohibits any funding for cloning to create babies,
reinforcing existing state law banning human reproductive cloning.
It’s totally focused on finding medical cures.
71 COULD REDUCE HEALTH CARE COSTS BY 
BILLIONS.
California has the nation’s highest total health care
spending costs—over $110 billion annually. A huge share of
those costs is caused by diseases that could be treated or
cured with stem cell therapies.
• If Prop. 71 leads to cures that reduce our health care 
costs by only 1%, it will pay for itself—and it could cut 
health care costs by tens of billions of dollars in future
decades.
For more information visit www.YESon71.com.
Vote YES on 71—IT COULD SAVE THE LIFE OF SOME-
ONE YOU LOVE.
ALAN D. CHERRINGTON, Ph.D., President
American Diabetes Association
CAROLYN ALDIGE, President
National Coalition for Cancer Research (NCCR)
JOAN SAMUELSON, President
Parkinson’s Action Network
ARGUMENT in Favor of Proposition 71
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ARGUMENT Against Proposition 71
REBUTTAL to Argument Against Proposition 71
NOBEL PRIZE WINNING MEDICAL RESEARCHERS,
DOCTORS, AND PATIENT GROUPS HAVE STUDIED
THIS MEASURE AND URGE: YES on 71.
• Stem cell research is the most promising area of research
aimed at finding breakthrough cures for currently incur-
able diseases and injuries affecting millions of people.
• 71 is a well-designed program to find those cures.
• It’s vitally needed because stem cell research is being
restricted by politics in Washington.
The claims by opponents are misleading political scare tactics.
71 SUPPORTS ALL TYPES OF STEM CELL RE-
SEARCH—including adult and cord blood stem cell
research.
71 FOCUSES ON RESEARCH BY NONPROFIT INSTI-
TUTIONS—NOT CORPORATIONS.
• It’s specifically designed to support the type of break-
through research conducted by universities, medical
schools, hospitals, and other nonprofit institutions.
71 REQUIRES PUBLIC ACCOUNTABILITY.
• 71 specifically says the institute overseeing the research
MUST COMPLY WITH OPEN MEETING LAWS.
• It requires PUBLIC HEARINGS and INDEPENDENT
AUDITS reviewed by the California State Controller
and an independent oversight committee.
71 PROTECTS CALIFORNIA’S BUDGET.
Prop. 71 is a good investment. Studies led by a Stanford
University economist project that 71 will generate millions
in new state revenues from royalties and new jobs, and that
new medical treatments and cures can REDUCE CALIFOR-
NIANS’ HEALTH CARE COSTS BY BILLIONS.
71 is endorsed by over 20 Nobel Prize Winning scientists,
medical groups representing over 35,000 California doctors
and nonprofit disease groups representing millions of suf-
fering patients.
VOTE YES on 71—TO FIND CURES THAT WILL SAVE
LIVES.
LEON THAL, M.D., Director
Alzheimer’s Disease Research Center, University of California
at San Diego
PAUL BERG, Ph.D., Nobel Laureate Professor of 
Cancer Research, 
Stanford University
ROGER GUILLEMIN, M.D., Ph.D., Nobel Laureate
Distinguished Professor, 
Salk Institute for Biological Studies
WE SUPPORT STEM CELL RESEARCH, NOT CORPO-
RATE WELFARE
It’s wrong to launch a costly new state bureaucracy when
vital programs for health, education, and police and fire
services are being cut. We cannot afford to pile another $3
billion in bonded debt on top of a state budget teetering on
the edge of financial ruin.
General Fund bond debt will grow from $33 Billion on
May 1, 2004, to a Legislative Accounting Office projection
of $50.75 Billion in debt by June 30, 2005—a staggering 54%
increase in just 14 months!
WHO BENEFITS?
Backers will cynically use images of suffering children
and people with disabilities in their commercials, but phar-
maceutical company executives and venture capitalists con-
tributed $2.6 million to put this measure on the ballot. By
getting taxpayers to fund their corporate research, they
stand to make billions with little risk.
NO ACCOUNTABILITY
And who will oversee how this money is spent? According
to the fine print, the proponents give themselves power to
exempt their “Institute for Regenerative Medicine” from
aspects of our California “open meeting” law (specifically
passed to stop this kind of backroom deal-making).
Why do proponents want to keep what they are doing a
secret? If we’re being asked to pay for this research, then it
should be freely available to all, not just to those who will be
“awarded” special contracts by the “Institute.” The initiative
also grants the “Institute” power to rewrite California’s med-
ical informed consent safeguards.
Most importantly, the fine print specifically prohibits the
Governor and Legislature from exercising oversight and 
control over how this money is spent—or misspent. Even if
the state teeters on the brink of financial ruin, our elected
representatives will still have to borrow and spend this
money, because the proponents are putting this money
grab into our Constitution.
BAD MEDICINE
Opponents of this boondoggle include liberals, con-
servatives, Republicans, Democrats, Independents, med-
ical professionals, and stem cell researchers. We all
strongly support Stem Cell Research, but oppose this bla-
tant taxpayer rip-off that lines the pockets of a few large
corporations.
If there was any doubt about the true motives of the cor-
porate promoters of this bond debt, one need only look at
what it doesn’t fund. The fine print does not initially fund
adult and cord blood stem cell research. Adult and cord
blood stem cell research has already produced more than
74 major medical breakthroughs, but this measure excludes
support for these proven areas of research, without a two-
thirds vote of the Institute’s “working group.”
Consider just one example: Cord blood stem cells are
being used to treat sickle cell anemia with a staggering suc-
cess rate of 90%. That’s real progress, helping real people,
but it may not receive one penny from this initiative.
Join with millions of your fellow citizens in demanding an
end to “corporate welfare” and bonded debt. This is no
time to spend billions we don’t have on a self-serving sham.
Vote “NO” on Proposition 71. It’s not what they say it is.
www.NoOn71.com
TOM MCCLINTOCK, California State Senator
JOHN M.W. MOORLACH, C.P.A.
Orange County Treasurer
H. REX GREENE, M.D., Cancer Center Director and
Bioethics Consultant
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TEXT OF PROPOSED LAWS
Proposition 71
This initiative measure is submitted to the people in accordance with
the provisions of Section 8 of Article II of the California Constitution.
This initiative measure expressly amends the California Constitution
by adding an article thereto; and amends a section of the Government
Code, and adds sections to the Health and Safety Code; therefore, new
provisions proposed to be added are printed in italic type to indicate that
they are new.
PROPOSED LAW
CALIFORNIA STEM CELL RESEARCH AND CURES INITIATIVE
SECTION 1. Title
This measure shall be known as the “California Stem Cell Research
and Cures Act.”
SEC. 2. Findings and Declarations
The people of California find and declare the following:
Millions of children and adults suffer from devastating diseases or
injuries that are currently incurable, including cancer, diabetes, heart
disease, Alzheimer’s, Parkinson’s, spinal cord injuries, blindness, Lou
Gehrig’s disease, HIV/AIDS, mental health disorders, multiple sclero-
sis, Huntington’s disease, and more than 70 other diseases and injuries.
Recently medical science has discovered a new way to attack chron-
ic diseases and injuries. The cure and treatment of these diseases can
potentially be accomplished through the use of new regenerative med-
ical therapies including a special type of human cells, called stem cells.
These life-saving medical breakthroughs can only happen if adequate
funding is made available to advance stem cell research, develop thera-
pies, and conduct clinical trials.
About half of California’s families have a child or adult who has suf-
fered or will suffer from a serious, often critical or terminal, medical
condition that could potentially be treated or cured with stem cell ther-
apies. In these cases of chronic illness or when patients face a medical
crisis, the health care system may simply not be able to meet the needs
of patients or control spiraling costs, unless therapy focus switches away
from maintenance and toward prevention and cures.
Unfortunately, the federal government is not providing adequate
funding necessary for the urgent research and facilities needed to devel-
op stem cell therapies to treat and cure diseases and serious injuries.
This critical funding gap currently prevents the rapid advancement of
research that could benefit millions of Californians.
The California Stem Cell Research and Cures Act will close this
funding gap by establishing an institute which will issue bonds to sup-
port stem cell research, emphasizing pluripotent stem cell and progeni-
tor cell research and other vital medical technologies, for the develop-
ment of life-saving regenerative medical treatments and cures.
SEC. 3. Purpose and Intent
It is the intent of the people of California in enacting this measure to:
Authorize an average of $295 million per year in bonds over a 
10-year period to fund stem cell research and dedicated facilities for 
scientists at California’s universities and other advanced medical
research facilities throughout the state.
Maximize the use of research funds by giving priority to stem cell
research that has the greatest potential for therapies and cures, specifi-
cally focused on pluripotent stem cell and progenitor cell research
among other vital research opportunities that cannot, or are unlikely to,
receive timely or sufficient federal funding, unencumbered by limita-
tions that would impede the research. Research shall be subject to
accepted patient disclosure and patient consent standards.
Assure that the research is conducted safely and ethically by includ-
ing provisions to require compliance with standards based on national
models that protect patient safety, patient rights, and patient privacy.
Prohibit the use of bond proceeds of this initiative for funding for
human reproductive cloning.
Improve the California health care system and reduce the long-term
health care cost burden on California through the development of ther-
apies that treat diseases and injuries with the ultimate goal to cure them.
Require strict fiscal and public accountability through mandatory
independent audits, open meetings, public hearings, and annual reports
to the public. Create an Independent Citizen’s Oversight Committee
composed of representatives of the University of California campuses
with medical schools; other California universities and California med-
ical research institutions; California disease advocacy groups; and
California experts in the development of medical therapies.
Protect and benefit the California budget: by postponing general
fund payments on the bonds for the first five years; by funding scientif-
ic and medical research that will significantly reduce state health care
costs in the future; and by providing an opportunity for the state to ben-
efit from royalties, patents, and licensing fees that result from the
research.
Benefit the California economy by creating projects, jobs, and ther-
apies that will generate millions of dollars in new tax revenues in our
state.
Advance the biotech industry in California to world leadership, as an
economic engine for California’s future.
SEC. 4. Article XXXV is added to the California Constitution, to
read:
Article XXXV. Medical Research
SECTION 1. There is hereby established the California Institute
for Regenerative Medicine.
SEC. 2. The institute shall have the following purposes:
(a) To make grants and loans for stem cell research, for research
facilities, and for other vital research opportunities to realize therapies,
protocols, and/or medical procedures that will result in, as speedily as
possible, the cure for, and/or substantial mitigation of, major diseases,
injuries, and orphan diseases.
(b) To support all stages of the process of developing cures, from
laboratory research through successful clinical trials.
(c) To establish the appropriate regulatory standards and oversight
bodies for research and facilities development.
SEC. 3. No funds authorized for, or made available to, the institute
shall be used for research involving human reproductive cloning.
SEC. 4. Funds authorized for, or made available to, the institute
shall be continuously appropriated without regard to fiscal year, be
available and used only for the purposes provided in this article, and
shall not be subject to appropriation or transfer by the Legislature or
the Governor for any other purpose.
SEC. 5. There is hereby established a right to conduct stem cell
research which includes research involving adult stem cells, cord blood
stem cells, pluripotent stem cells, and/or progenitor cells. Pluripotent
stem cells are cells that are capable of self-renewal, and have broad
potential to differentiate into multiple adult cell types. Pluripotent stem
cells may be derived from somatic cell nuclear transfer or from surplus
products of in vitro fertilization treatments when such products are
donated under appropriate informed consent procedures. Progenitor
cells are multipotent or precursor cells that are partially differentiated,
but retain the ability to divide and give rise to differentiated cells.
SEC. 6. Notwithstanding any other provision of this Constitution
or any law, the institute, which is established in state government, may
utilize state issued tax-exempt and taxable bonds to fund its operations,
medical and scientific research, including therapy development through
clinical trials, and facilities.
SEC. 7. Notwithstanding any other provision of this Constitution,
including Article VII, or any law, the institute and its employees are
exempt from civil service.
SEC. 5. Chapter 3 (commencing with Section 125290.10) is
added to Part 5 of Division 106 of the Health and Safety Code, to read:
CHAPTER 3. CALIFORNIA STEM CELL RESEARCH AND CURES
BOND ACT
Article 1. California Stem Cell Research and Cures Act
125290.10. General—Independent Citizen’s Oversight Committee
(ICOC)
This chapter implements Article XXXV of the California
Constitution, which established the California Institute for Regenerative
Medicine (institute).
125290.15. Creation of the ICOC
There is hereby created the Independent Citizen’s Oversight
Committee, hereinafter, the ICOC, which shall govern the institute and
is hereby vested with full power, authority, and jurisdiction over the
institute.
125290.20. ICOC Membership; Appointments; Terms of Office
(a) ICOC Membership
The ICOC shall have 29 members, appointed as follows:
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(1) The Chancellors of the University of California at San
Francisco, Davis, San Diego, Los Angeles, and Irvine, shall each
appoint an executive officer from his or her campus.
(2) The Governor, the Lieutenant Governor, the Treasurer, and the
Controller shall each appoint an executive officer from the following
three categories:
(A) A California university, excluding the five campuses of the
University of California described in paragraph (1), that has demon-
strated success and leadership in stem cell research, and that has:
(i) A nationally ranked research hospital and medical school; this
criteria will apply to only two of the four appointments.
(ii) A recent proven history of administering scientific and/or med-
ical research grants and contracts in an average annual range exceed-
ing one hundred million dollars ($100,000,000).
(iii) A ranking, within the past five years, in the top 10 United States
universities with the highest number of life science patents or that has
research or clinical faculty who are members of the National Academy
of Sciences.
(B) A California nonprofit academic and research institution that is
not a part of the University of California, that has demonstrated suc-
cess and leadership in stem cell research, and that has:
(i) A nationally ranked research hospital or that has research or
clinical faculty who are members of the National Academy of Sciences.
(ii) A proven history in the last five years of managing a research
budget in the life sciences exceeding twenty million dollars
($20,000,000).
(C) A California life science commercial entity that is not actively
engaged in researching or developing therapies with pluripotent or pro-
genitor stem cells, that has a background in implementing successful
experimental medical therapies, and that has not been awarded, or
applied for, funding by the institute at the time of appointment. A board
member of that entity with a successful history of developing innovative
medical therapies may be appointed in lieu of an executive officer.
(D) Only one member shall be appointed from a single university,
institution, or entity. The executive officer of a California university, a
nonprofit research institution or life science commercial entity who is
appointed as a member, may from time to time delegate those duties to
an executive officer of the entity or to the dean of the medical school, if
applicable.
(3) The Governor, the Lieutenant Governor, the Treasurer, and the
Controller shall appoint members from among California representa-
tives of California regional, state, or national disease advocacy groups,
as follows:
(A) The Governor shall appoint two members, one from each of the
following disease advocacy groups: spinal cord injury and Alzheimer’s
disease.
(B) The Lieutenant Governor shall appoint two members, one from
each of the following disease advocacy groups: type II diabetes and
multiple sclerosis or amyotrophic lateral sclerosis.
(C) The Treasurer shall appoint two members, one from each of the
following disease groups: type I diabetes and heart disease.
(D) The Controller shall appoint two members, one from each of the
following disease groups: cancer and Parkinson’s disease.
(4) The Speaker of the Assembly shall appoint a member from
among California representatives of a California regional, state, or
national mental health disease advocacy group.
(5) The President pro Tempore of the Senate shall appoint a mem-
ber from among California representatives of a California regional,
state, or national HIV/AIDS disease advocacy group.
(6) A chairperson and vice chairperson who shall be elected by the
ICOC members. Within 40 days of the effective date of this act, each
constitutional officer shall nominate a candidate for chairperson and
another candidate for vice chairperson. The chairperson and vice
chairperson shall each be elected for a term of six years. The chairper-
son and vice chairperson of ICOC shall be full or part time employees
of the institute and shall meet the following criteria:
(A) Mandatory Chairperson Criteria
(i) Documented history in successful stem cell research advocacy.
(ii) Experience with state and federal legislative processes that 
must include some experience with medical legislative approvals of
standards and/or funding.
(iii) Qualified for appointment pursuant to paragraph (3), (4), or (5)
of subdivision (a).
(iv) Cannot be concurrently employed by or on leave from any
prospective grant or loan recipient institutions in California.
(B) Additional Criteria for Consideration:
(i) Experience with governmental agencies or institutions (either
executive or board position).
(ii) Experience with the process of establishing government standards
and procedures.
(iii) Legal experience with the legal review of proper governmental
authority for the exercise of government agency or government institu-
tional powers.
(iv) Direct knowledge and experience in bond financing.
The vice chairperson shall satisfy clauses (i), (iii), and (iv) of sub-
paragraph (A). The vice chairperson shall be selected from among indi-
viduals who have attributes and experience complementary to those of
the chairperson, preferably covering the criteria not represented by the
chairperson’s credentials and experience.
(b) Appointment of ICOC Members
(1) All appointments shall be made within 40 days of the effective
date of this act. In the event that any of the appointments are not com-
pleted within the permitted timeframe, the ICOC shall proceed to oper-
ate with the appointments that are in place, provided that at least 60
percent of the appointments have been made.
(2) Forty-five days after the effective date of the measure adding this
chapter, the State Controller and the Treasurer, or if only one is avail-
able within 45 days, the other shall convene a meeting of the appointed
members of the ICOC to elect a chairperson and vice chairperson from
among the individuals nominated by the constitutional officers pursuant
to paragraph (6) of subdivision (a).
(c) ICOC Member Terms of Office
(1) The members appointed pursuant to paragraphs (1), (3), (4),
and (5) of subdivision (a) shall serve eight-year terms, and all other
members shall serve six-year terms. Members shall serve a maximum of
two terms.
(2) If a vacancy occurs within a term, the appointing authority shall
appoint a replacement member within 30 days to serve the remainder
of the term.
(3) When a term expires, the appointing authority shall appoint a
member within 30 days. ICOC members shall continue to serve until
their replacements are appointed.
125290.25. Majority Vote of Quorum
Actions of the ICOC may be taken only by a majority vote of a quo-
rum of the ICOC.
125290.30. Public and Financial Accountability Standards
(a) Annual Public Report
The institute shall issue an annual report to the public which sets
forth its activities, grants awarded, grants in progress, research accom-
plishments, and future program directions. Each annual report shall
include, but not be limited to, the following: the number and dollar
amounts of research and facilities grants; the grantees for the prior
year; the institute’s administrative expenses; an assessment of the avail-
ability of funding for stem cell research from sources other than the
institute; a summary of research findings, including promising new
research areas; an assessment of the relationship between the institute’s
grants and the overall strategy of its research program; and a report of
the institute’s strategic research and financial plans.
(b) Independent Financial Audit for Review by State Controller
The institute shall annually commission an independent financial
audit of its activities from a certified public accounting firm, which shall
be provided to the State Controller, who shall review the audit and
annually issue a public report of that review.
(c) Citizen’s Financial Accountability Oversight Committee
There shall be a Citizen’s Financial Accountability Oversight
Committee chaired by the State Controller. This committee shall review
the annual financial audit, the State Controller’s report and evaluation
of that audit, and the financial practices of the institute. The State
Controller, the State Treasurer, the President pro Tempore of the Senate,
the Speaker of the Assembly, and the Chairperson of the ICOC shall
each appoint a public member of the committee. Committee members
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shall have medical backgrounds and knowledge of relevant financial
matters. The committee shall provide recommendations on the institute’s
financial practices and performance. The State Controller shall provide
staff support. The committee shall hold a public meeting, with appropri-
ate notice, and with a formal public comment period. The committee
shall evaluate public comments and include appropriate summaries in its
annual report. The ICOC shall provide funds for the per diem expenses
of the committee members and for publication of the annual report.
(d) Public Meeting Laws
(1) The ICOC shall hold at least two public meetings per year, 
one of which will be designated as the institute’s annual meeting. The
ICOC may hold additional meetings as it determines are necessary or
appropriate.
(2) The Bagley-Keene Open Meeting Act, Article 9 (commencing
with Section 11120) of Chapter 1 of Part 1 of Division 3 of Title 2 of the
Government Code, shall apply to all meetings of the ICOC, except as
otherwise provided in this section. The ICOC shall award all grants,
loans, and contracts in public meetings and shall adopt all governance,
scientific, medical, and regulatory standards in public meetings.
(3) The ICOC may conduct closed sessions as permitted by the
Bagley-Keene Open Meeting Act, under Section 11126 of the
Government Code. In addition, the ICOC may conduct closed sessions
when it meets to consider or discuss:
(A) Matters involving information relating to patients or medical
subjects, the disclosure of which would constitute an unwarranted 
invasion of personal privacy.
(B) Matters involving confidential intellectual property or work
product, whether patentable or not, including, but not limited to, any
formula, plan, pattern, process, tool, mechanism, compound, procedure,
production data, or compilation of information, which is not patented,
which is known only to certain individuals who are using it to fabricate,
produce, or compound an article of trade or a service having commer-
cial value and which gives its user an opportunity to obtain a business
advantage over competitors who do not know it or use it.
(C) Matters involving prepublication, confidential scientific
research or data.
(D) Matters concerning the appointment, employment, perform-
ance, compensation, or dismissal of institute officers and employees.
Action on compensation of the institute’s officers and employees shall
only be taken in open session.
(4) The meeting required by paragraph (2) of subdivision (b) of
Section 125290.20 shall be deemed to be a special meeting for the pur-
poses of Section 11125.4 of the Government Code.
(e) Public Records
(1) The California Public Records Act, Article 1 (commencing with
Section 6250) of Chapter 3.5 of Division 7 of Title 1 of the Government
Code, shall apply to all records of the institute, except as otherwise pro-
vided in this section.
(2) Nothing in this section shall be construed to require disclosure
of any records that are any of the following:
(A) Personnel, medical, or similar files, the disclosure of which
would constitute an unwarranted invasion of personal privacy.
(B) Records containing or reflecting confidential intellectual prop-
erty or work product, whether patentable or not, including, but not lim-
ited to, any formula, plan, pattern, process, tool, mechanism, com-
pound, procedure, production data, or compilation of information,
which is not patented, which is known only to certain individuals who
are using it to fabricate, produce, or compound an article of trade or a
service having commercial value and which gives its user an opportu-
nity to obtain a business advantage over competitors who do not know
it or use it.
(C) Prepublication scientific working papers or research data.
(f) Competitive Bidding
(1) The institute shall, except as otherwise provided in this section,
be governed by the competitive bidding requirements applicable to the
University of California, as set forth in Article 1 (commencing with
Section 10500) of Chapter 2.1 of Part 2 of Division 2 of the Public
Contract Code.
(2) For all institute contracts, the ICOC shall follow the procedures
required of the Regents by Article 1 (commencing with Section 10500)
of Chapter 2.1 of Part 2 of Division 2 of the Public Contract Code with
respect to contracts let by the University of California.
(3) The requirements of this section shall not be applicable to grants
or loans approved by the ICOC.
(4) Except as provided in this section, the Public Contract Code
shall not apply to contracts let by the institute.
(g) Conflicts of Interest
(1) The Political Reform Act, Title 9 (commencing with Sec-
tion 81000) of the Government Code, shall apply to the institute and to
the ICOC, except as provided in this section and in subdivision (e) of
Section 125290.50.
(A) No member of the ICOC shall make, participate in making, or
in any way attempt to use his or her official position to influence a deci-
sion to approve or award a grant, loan, or contract to his or her employ-
er, but a member may participate in a decision to approve or award a
grant, loan, or contract to a nonprofit entity in the same field as his or
her employer.
(B) A member of the ICOC may participate in a decision to approve
or award a grant, loan, or contract to an entity for the purpose of
research involving a disease from which a member or his or her imme-
diate family suffers or in which the member has an interest as a repre-
sentative of a disease advocacy organization.
(C) The adoption of standards is not a decision subject to this 
section.
(2) Service as a member of the ICOC by a member of the faculty or
administration of any system of the University of California shall not,
by itself, be deemed to be inconsistent, incompatible, in conflict with, or
inimical to the duties of the ICOC member as a member of the faculty
or administration of any system of the University of California and shall
not result in the automatic vacation of either such office. Service as a
member of the ICOC by a representative or employee of a disease advo-
cacy organization, a nonprofit academic and research institution, or a
life science commercial entity shall not be deemed to be inconsistent,
incompatible, in conflict with, or inimical to the duties of the ICOC
member as a representative or employee of that organization, institu-
tion, or entity.
(3) Section 1090 of the Government Code shall not apply to any
grant, loan, or contract made by the ICOC except where both of the fol-
lowing conditions are met:
(A) The grant, loan, or contract directly relates to services to be
provided by any member of the ICOC or the entity the member 
represents or financially benefits the member or the entity he or she
represents.
(B) The member fails to recuse himself or herself from making, par-
ticipating in making, or in any way attempting to use his or her official
position to influence a decision on the grant loan or contract.
(h) Patent Royalties and License Revenues Paid to the State of
California
The ICOC shall establish standards that require that all grants and
loan awards be subject to intellectual property agreements that balance
the opportunity of the State of California to benefit from the patents,
royalties, and licenses that result from basic research, therapy develop-
ment, and clinical trials with the need to assure that essential medical
research is not unreasonably hindered by the intellectual property
agreements.
(i) Preference for California Suppliers
The ICOC shall establish standards to ensure that grantees purchase
goods and services from California suppliers to the extent reasonably
possible, in a good faith effort to achieve a goal of more than 50 percent
of such purchases from California suppliers.
125290.35. Medical and Scientific Accountability Standards
(a) Medical Standards
In order to avoid duplication or conflicts in technical standards for
scientific and medical research, with alternative state programs, the
institute will develop its own scientific and medical standards to carry
out the specific controls and intent of the act, notwithstanding subdivi-
sion (b) of Section 125300, Sections 125320, 125118, 125118.5,
125119, 125119.3 and 125119.5, or any other current or future state
laws or regulations dealing with the study and research of pluripotent
stem cells and/or progenitor cells, or other vital research opportunities,
except Section 125315. The ICOC, its working committees, and its
grantees shall be governed solely by the provisions of this act in the
establishment of standards, the award of grants, and the conduct of
grants awarded pursuant to this act.
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(b) The ICOC shall establish standards as follows:
(1) Informed Consent
Standards for obtaining the informed consent of research donors,
patients, or participants, which initially shall be generally based on the
standards in place on January 1, 2003, for all research funded by the
National Institutes of Health, with modifications to adapt to the mission
and objectives of the institute.
(2) Controls on Research Involving Humans
Standards for the review of research involving human subjects which
initially shall be generally based on the Institutional Review Board
standards promulgated by the National Institutes of Health and in effect
on January 1, 2003, with modifications to adapt to the mission and
objectives of the institute.
(3) Prohibition on Compensation
Standards prohibiting compensation to research donors or partici-
pants, while permitting reimbursement of expenses.
(4) Patient Privacy Laws
Standards to assure compliance with state and federal patient priva-
cy laws.
(5) Limitations on Payments for Cells
Standards limiting payments for the purchase of stem cells or stem
cell lines to reasonable payment for the removal, processing, dispos-
al, preservation, quality control, storage, transplantation, or implan-
tation or legal transaction or other administrative costs associated
with these medical procedures and specifically including any required
payments for medical or scientific technologies, products, or process-
es for royalties, patent, or licensing fees or other costs for intellectual
property.
(6) Time Limits for Obtaining Cells
Standards setting a limit on the time during which cells may be
extracted from blastocysts, which shall initially be 8 to 12 days after cell
division begins, not counting any time during which the blastocysts
and/or cells have been stored frozen.
125290.40. ICOC Functions
The ICOC shall perform the following functions:
(a) Oversee the operations of the institute.
(b) Develop annual and long-term strategic research and financial
plans for the institute.
(c) Make final decisions on research standards and grant awards in
California.
(d) Ensure the completion of an annual financial audit of the insti-
tute’s operations.
(e) Issue public reports on the activities of the institute.
(f) Establish policies regarding intellectual property rights arising
from research funded by the institute.
(g) Establish rules and guidelines for the operation of the ICOC and
its working groups.
(h) Perform all other acts necessary or appropriate in the exercise
of its power, authority, and jurisdiction over the institute.
(i) Select members of the working groups.
(j) Adopt, amend, and rescind rules and regulations to carry out the
purposes and provisions of this chapter, and to govern the procedures
of the ICOC. Except as provided in subdivision (k), these rules and reg-
ulations shall be adopted in accordance with the Administrative
Procedure Act (Government Code, Title 2, Division 3, Part 1, Chapter
4.5, Sections 11371 et seq.).
(k) Notwithstanding the Administrative Procedure Act (APA), and
in order to facilitate the immediate commencement of research covered
by this chapter, the ICOC may adopt interim regulations without com-
pliance with the procedures set forth in the APA. The interim regula-
tions shall remain in effect for 270 days unless earlier superseded by
regulations adopted pursuant to the APA.
(l) Request the issuance of bonds from the California Stem Cell
Research and Cures Finance Committee and loans from the Pooled
Money Investment Board.
(m) May annually modify its funding and finance programs to opti-
mize the institute’s ability to achieve the objective that its activities be
revenue-positive for the State of California during its first five years of
operation without jeopardizing the progress of its core medical and
scientific research program.
(n) Notwithstanding Section 11005 of the Government Code, accept
additional revenue and real and personal property, including, but not
limited to, gifts, royalties, interest, and appropriations that may be
used to supplement annual research grant funding and the operations
of the institute.
125290.45. ICOC Operations
(a) Legal Actions and Liability
(1) The institute may sue and be sued.
(2) Based upon ICOC standards, institute grantees shall indemnify
or insure and hold the institute harmless against any and all losses,
claims, damages, expenses, or liabilities, including attorneys’ fees, aris-
ing from research conducted by the grantee pursuant to the grant,
and/or, in the alternative, grantees shall name the institute as an addi-
tional insured and submit proof of such insurance.
(3) Given the scientific, medical, and technical nature of the issues
facing the ICOC, and notwithstanding Section 11042 of the
Government Code, the institute is authorized to retain outside counsel
when the ICOC determines that the institute requires specialized serv-
ices not provided by the Attorney General’s office.
(4) The institute may enter into any contracts or obligations which
are authorized or permitted by law.
(b) Personnel
(1) The ICOC shall from time to time determine the total number of
authorized employees for the institute, up to a maximum of 50 employ-
ees, excluding members of the working groups, who shall not be consid-
ered institute employees. The ICOC shall select a chairperson, vice
chairperson and president who shall exercise all of the powers delegat-
ed to them by the ICOC. The following functions apply to the chairper-
son, vice chairperson, and president:
(A) The chairperson’s primary responsibilities are to manage the
ICOC agenda and work flow including all evaluations and approvals
of scientific and medical working group grants, loans, facilities, and
standards evaluations, and to supervise all annual reports and public
accountability requirements; to manage and optimize the institute’s
bond financing plans and funding cash flow plan; to interface with
the California Legislature, the United States Congress, the California
health care system, and the California public; to optimize all finan-
cial leverage opportunities for the institute; and to lead negotiations
for intellectual property agreements, policies, and contract terms. The
chairperson shall also serve as a member of the Scientific and
Medical Accountability Standards Working Group and the Scientific
and Medical Research Facilities Working Group and as an ex-officio
member of the Scientific and Medical Research Funding Working
Group. The vice chairperson’s primary responsibilities are to support
the chairperson in all duties and to carry out those duties in the chair-
person’s absence.
(B) The president’s primary responsibilities are to serve as the chief
executive of the institute; to recruit the highest scientific and medical
talent in the United States to serve the institute on its working groups;
to serve the institute on its working groups; to direct ICOC staff and
participate in the process of supporting all working group requirements
to develop recommendations on grants, loans, facilities, and standards
as well as to direct and support the ICOC process of evaluating and
acting on those recommendations, the implementation of all decisions
on these and general matters of the ICOC; to hire, direct, and manage
the staff of the institute; to develop the budgets and cost control pro-
grams of the institute; to manage compliance with all rules and regula-
tions on the ICOC, including the performance of all grant recipients;
and to manage and execute all intellectual property agreements and
any other contracts pertaining to the institute or research it funds.
(2) Each member of the ICOC except, the chairperson, vice chair-
person, and president, shall receive a per diem of one hundred dollars
($100) per day (adjusted annually for cost of living) for each day actu-
ally spent in the discharge of the member’s duties, plus reasonable and
necessary travel and other expenses incurred in the performance of the
member’s duties.
(3) The ICOC shall establish daily consulting rates and expense
reimbursement standards for the non-ICOC members of all of its 
working groups.
(4) Notwithstanding Section 19825 of the Government Code, the
ICOC shall set compensation for the chairperson, vice chairperson,
and president and other officers, and for the scientific, medical, techni-
cal, and administrative staff of the institute within the range of compen-
sation levels for executive officers and scientific, medical, technical,
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and administrative staff of medical schools within the University of
California system and the nonprofit academic and research institutions
described in paragraph (2) of subdivision (a) of Section 125290.20.
125290.50. Scientific and Medical Working Groups-General
(a) The institute shall have, and there is hereby established, three
separate scientific and medical working groups as follows:
(1) Scientific and Medical Research Funding Working Group.
(2) Scientific and Medical Accountability Standards Working Group.
(3) Scientific and Medical Research Facilities Working Group.
(b) Working Group Members
Appointments of scientific and medical working group members shall
be made by a majority vote of a quorum of the ICOC, within 30 days of
the election and appointment of the initial ICOC members. The working
group members’ terms shall be six years except that, after the first 
six-year terms, the members’ terms will be staggered so that one-third
of the members shall be elected for a term that expires two years later, 
one-third of the members shall be elected for a term that expires four
years later, and one-third of the members shall be elected for a term that
expires six years later. Subsequent terms are for six years. Working
group members may serve a maximum of two consecutive terms.
(c) Working Group Meetings
Each scientific and medical working group shall hold at least four
meetings per year, one of which shall be designated as its annual meeting.
(d) Working Group Recommendations to the ICOC
Recommendations of each of the working groups may be forwarded
to the ICOC only by a vote of a majority of a quorum of the members of
each working group. If 35 percent of the members of any working group
join together in a minority position, a minority report may be submitted
to the ICOC. The ICOC shall consider the recommendations of the
working groups in making its decisions on applications for research and
facility grants and loan awards and in adopting regulatory standards.
Each working group shall recommend to ICOC rules, procedures, and
practices for that working group.
(e) Conflict of Interest
(1) The ICOC shall adopt conflict of interest rules, based on stan-
dards applicable to members of scientific review committees of the
National Institutes of Health, to govern the participation of non-ICOC
working group members.
(2) The ICOC shall appoint an ethics officer from among the staff of
the institute.
(3) Because the working groups are purely advisory and have no
final decisionmaking authority, members of the working groups shall
not be considered public officials, employees, or consultants for purpos-
es of the Political Reform Act (Title 9 (commencing with Section 81000)
of the Government Code), Sections 1090 and 19990 of the Government
Code, and Sections 10516 and 10517 of the Public Contract Code.
(f) Working Group Records
All records of the working groups submitted as part of the working
groups’ recommendations to the ICOC for approval shall be subject to
the Public Records Act. Except as provided in this subdivision, the work-
ing groups shall not be subject to the provisions of Article 9 (commenc-
ing with Section 11120) of Chapter 1 of Part 1 of Division 3 of Title 2
of the Government Code, or Article 1 (commencing with Section 6250)
of Chapter 3.5 of Division 7 of Title 1 of the Government Code.
125290.55. Scientific and Medical Accountability Standards
Working Group
(a) Membership
The Scientific and Medical Accountability Standards Working Group
shall have 19 members as follows:
(1) Five ICOC members from the 10 groups that focus on disease-
specific areas described in paragraphs (3), (4), and (5) of subdivision
(a) of Section 125290.20.
(2) Nine scientists and clinicians nationally recognized in the field
of pluripotent and progenitor cell research.
(3) Four medical ethicists.
(4) The Chairperson of the ICOC.
(b) Functions
The Scientific and Medical Accountability Standards Working Group
shall have the following functions:
(1) To recommend to the ICOC scientific, medical, and ethical 
standards.
(2) To recommend to the ICOC standards for all medical, socioeco-
nomic, and financial aspects of clinical trials and therapy delivery to
patients, including, among others, standards for safe and ethical proce-
dures for obtaining materials and cells for research and clinical efforts
for the appropriate treatment of human subjects in medical research
consistent with paragraph (2) of subdivision (b) of Section 125290.35,
and to ensure compliance with patient privacy laws.
(3) To recommend to the ICOC modification of the standards
described in paragraphs (1) and (2) as needed.
(4) To make recommendations to the ICOC on the oversight of
funded research to ensure compliance with the standards described in
paragraphs (1) and (2).
(5) To advise the ICOC, the Scientific and Medical Research
Funding Working Group, and the Scientific and Medical Research
Facilities Working Group, on an ongoing basis, on relevant ethical and
regulatory issues.
125290.60. Scientific and Medical Research Funding Working
Group
(a) Membership
The Scientific and Medical Research Funding Working Group shall
have 23 members as follows:
(1) Seven ICOC members from the 10 disease advocacy group
members described in paragraphs (3), (4), and (5) of subdivision (a) of
Section 125290.20.
(2) Fifteen scientists nationally recognized in the field of stem cell
research.
(3) The Chairperson of the ICOC.
(b) Functions
The Scientific and Medical Research Funding Working Group shall
perform the following functions:
(1) Recommend to the ICOC interim and final criteria, standards,
and requirements for considering funding applications and for award-
ing research grants and loans.
(2) Recommend to the ICOC standards for the scientific and med-
ical oversight of awards.
(3) Recommend to the ICOC any modifications of the criteria, stan-
dards, and requirements described in paragraphs (1) and (2) above as
needed.
(4) Review grant and loan applications based on the criteria,
requirements, and standards adopted by the ICOC and make recom-
mendations to the ICOC for the award of research, therapy develop-
ment, and clinical trial grants and loans.
(5) Conduct peer group progress oversight reviews of grantees to
ensure compliance with the terms of the award, and report to the ICOC
any recommendations for subsequent action.
(6) Recommend to the ICOC standards for the evaluation of
grantees to ensure that they comply with all applicable requirements.
Such standards shall mandate periodic reporting by grantees and
shall authorize the Scientific and Medical Research Funding Working
Group to audit a grantee and forward any recommendations for action
to the ICOC.
(7) Recommend its first grant awards within 60 days of the issuance
of the interim standards.
(c) Recommendations for Awards
Award recommendations shall be based upon a competitive evalua-
tion as follows:
(1) Only the 15 scientist members of the Scientific and Medical
Research Funding Working Group shall score grant and loan award
applications for scientific merit. Such scoring shall be based on scien-
tific merit in three separate classifications—research, therapy develop-
ment, and clinical trials, on criteria including the following:
(A) A demonstrated record of achievement in the areas of pluripo-
tent stem cell and progenitor cell biology and medicine, unless the
research is determined to be a vital research opportunity.
(B) The quality of the research proposal, the potential for achieving
significant research, or clinical results, the timetable for realizing such
significant results, the importance of the research objectives, and the
innovativeness of the proposed research.
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(C) In order to ensure that institute funding does not duplicate or
supplant existing funding, a high priority shall be placed on funding
pluripotent stem cell and progenitor cell research that cannot, or is
unlikely to, receive timely or sufficient federal funding, unencumbered
by limitations that would impede the research. In this regard, other
research categories funded by the National Institutes of Health shall not
be funded by the institute.
(D) Notwithstanding subparagraph (C), other scientific and med-
ical research and technologies and/or any stem cell research proposal
not actually funded by the institute under subparagraph (C) may be
funded by the institute if at least two-thirds of a quorum of the members
of the Scientific and Medical Research Funding Working Group recom-
mend to the ICOC that such a research proposal is a vital research
opportunity.
125290.65. Scientific and Medical Facilities Working Group
(a) Membership
The Scientific and Medical Research Facilities Working Group shall
have 11 members as follows:
(1) Six members of the Scientific and Medical Research Funding
Working Group.
(2) Four real estate specialists. To be eligible to serve on the
Scientific and Medical Research Facilities Working Group, a real estate
specialist shall be a resident of California, shall be prohibited from
receiving compensation from any construction or development entity
providing specialized services for medical research facilities, and shall
not provide real estate facilities brokerage services for any applicant
for, or any funding by the Scientific and Medical Research Facilities
Working Group and shall not receive compensation from any recipient
of institute funding grants.
(3) The Chairperson of the ICOC.
(b) Functions
The Scientific and Medical Research Facilities Working Group shall
perform the following functions:
(1) Make recommendations to the ICOC on interim and final crite-
ria, requirements, and standards for applications for, and the awarding
of, grants and loans for buildings, building leases, and capital equip-
ment; those standards and requirements shall include, among others:
(A) Facility milestones and timetables for achieving such milestones.
(B) Priority for applications that provide for facilities that will be
available for research no more than two years after the grant award.
(C) The requirement that all funded facilities and equipment be
located solely within California.
(D) The requirement that grantees comply with reimbursable build-
ing cost standards, competitive building leasing standards, capital
equipment cost standards, and reimbursement standards and terms rec-
ommended by the Scientific and Medical Facilities Funding Working
Group, and adopted by the ICOC.
(E) The requirement that grantees shall pay all workers employed
on construction or modification of the facility funded by facilities
grants or loans of the institute, the general prevailing rate of per diem
wages for work of a similar character in the locality in which work on
the facility is performed, and not less than the general prevailing rate
of per diem wages for holiday and overtime work fixed as provided in
Chapter 1 (commencing with Section 1720) of Part 7 of Division 2 of
the Labor Code.
(F) The requirement that grantees be not-for-profit entities.
(G) The requirement that awards be made on a competitive basis,
with the following minimum requirements:
(i) That the grantee secure matching funds from sources other than
the institute equal to at least 20 percent of the award. Applications of
equivalent merit, as determined by the Scientific and Medical Research
Funding Working Group, considering research opportunities to be con-
ducted in the proposed research facility, shall receive priority to the
extent that they provide higher matching fund amounts. The Scientific
and Medical Research Facilities Working Group may recommend waiv-
ing the matching fund requirement in extraordinary cases of high merit
or urgency.
(ii) That capital equipment costs and capital equipment loans be
allocated when equipment costs can be recovered in part by the grantee
from other users of the equipment.
(2) Make recommendations to the ICOC on oversight procedures to
ensure grantees’ compliance with the terms of an award.
125290.70. Appropriation and Allocation of Funding
(a) Moneys in the California Stem Cell Research and Cures Fund
shall be allocated as follows:
(1) (A) No less than 97 percent of the proceeds of the bonds author-
ized pursuant to Section 125291.30, after allocation of bond proceeds
to purposes described in paragraphs (4) and (5) of subdivision (a) of
Section 125291.20, shall be used for grants and grant oversight as pro-
vided in this chapter.
(B) Not less than 90 percent of the amount used for grants shall be
used for research grants, with no more than the following amounts as
stipulated below to be committed during the first 10 years of grant mak-
ing by the institute, with each year’s commitments to be advanced over
a period of one to seven years, except that any such funds that are not
committed may be carried over to one or more following years. The max-
imum amount of research funding to be allocated annually as follows:
Year 1, 5.6 percent; Year 2, 9.4 percent; Year 3, 9.4 percent; Year 4, 
11.3 percent; Year 5, 11.3 percent; Year 6, 11.3 percent; Year 7, 11.3 percent;
Year 8, 11.3 percent; Year 9, 11.3 percent; and Year 10, 7.5 percent.
(C) Not more than 3 percent of the proceeds of bonds authorized by
Section 125291.30 may be used by the institute for research and
research facilities implementation costs, including the development,
administration, and oversight of the grant making process and the oper-
ations of the working groups.
(2) Not more than 3 percent of the proceeds of the bonds authorized
pursuant to Section 125291.30 shall be used for the costs of general
administration of the institute.
(3) In any single year any new research funding to any single
grantee for any program year is limited to no more than 2 percent of the
total bond authorization under this chapter. This limitation shall be
considered separately for each new proposal without aggregating any
prior year approvals that may fund research activities. This requirement
shall be determinative, unless 65 percent of a quorum of the ICOC
approves a higher limit for that grantee.
(4) Recognizing the priority of immediately building facilities that
ensure the independence of the scientific and medical research of the
institute, up to 10 percent of the proceeds of the bonds authorized pur-
suant to Section 125291.30, net of costs described in paragraphs (2),
(4), and (5) of subdivision (a) of Section 125291.20 shall be allocated
for grants to build scientific and medical research facilities of nonprof-
it entities which are intended to be constructed in the first five years.
(5) The institute shall limit indirect costs to 25 percent of a research
award, excluding amounts included in a facilities award, except that the
indirect cost limitation may be increased by that amount by which the
grantee provides matching funds in excess of 20 percent of the grant
amount.
(b) To enable the institute to commence operating during the first
six months following the adoption of the measure adding this chapter,
there is hereby appropriated from the General Fund as a temporary
start-up loan to the institute three million dollars ($3,000,000) for ini-
tial administrative and implementation costs. All loans to the institute
pursuant to this appropriation shall be repaid to the General Fund
within 12 months of each loan draw from the proceeds of bonds sold
pursuant to Section 125291.30.
(c) The institute’s funding schedule is designed to create a positive
tax revenue stream for the State of California during the institute’s first
five calendar years of operations, without drawing funds from the
General Fund for principal and interest payments for those first five
calendar years.
Article 2. California Stem Cell Research and Cures 
Bond Act of 2004
125291.10. This article shall be known, and may be cited, as the
California Stem Cell Research and Cures Bond Act of 2004.
125291.15. As used in this article, the following terms have the 
following meaning:
(a) “Act” means the California Stem Cell Research and Cures Bond
Act constituting Chapter 3 (commencing with Section 125290.10) of
Part 5 of Division 106.
(b) “Board” or “institute” means the California Institute for
Regenerative Medicine designated in accordance with subdivision (b)
of Section 125291.40.
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(c) “Committee” means the California Stem Cell Research and
Cures Finance Committee created pursuant to subdivision (a) of 
Section 125291.40.
(d) “Fund” means the California Stem Cell Research and Cures
Fund created pursuant to Section 125291.25.
(e) “Interim debt” means any interim loans pursuant to subdivision
(b) of Section 125290.70, and Sections 125291.60 and 125291.65, bond
anticipation notes or commercial paper notes issued to make deposits
into the fund and which will be paid from the proceeds of bonds issued
pursuant to this article.
125291.20. (a) Notwithstanding Section 13340 of the Government
Code or any other provision of law, moneys in the fund are appropriat-
ed without regard to fiscal years to the institute for the purpose of 
(1) making grants or loans to fund research and construct facilities for
research, all as described in and pursuant to the act, (2) paying gener-
al administrative costs of the institute (not to exceed 3 percent of the net
proceeds of each sale of bonds), (3) paying the annual administration
costs of the interim debt or bonds after December 31 of the fifth full cal-
endar year after this article takes effect, (4) paying the costs of issuing
interim debt, paying the annual administration costs of the interim debt
until and including December 31 of the fifth full calendar year after this
article takes effect, and paying interest on interim debt, if such interim
debt is incurred or issued on or prior to December 31 of the fifth full
calendar year after this article takes effect, and (5) paying the costs of
issuing bonds, paying the annual administration costs of the bonds until
and including December 31 of the fifth full calendar year after this arti-
cle takes effect, and paying interest on bonds that accrues on or prior to
December 31 of the fifth full calendar year after this article takes effect
(except that such limitation does not apply to premium and accrued
interest as provided in Section 125291.70). In addition, moneys in the
fund or other proceeds of the sale of bonds authorized by this article
may be used to pay principal of or redemption premium on any interim
debt issued prior to the issuance of bonds authorized by this article.
Moneys deposited in the fund from the proceeds of interim debt may be
used to pay general administrative costs of the institute without regard
to the 3 percent limit set forth in (2) above, so long as such 3 percent
limit is satisfied for each issue of bonds.
(b) Repayment of principal and interest on any loans made by the
institute pursuant to this article shall be deposited in the fund and used to
make additional grants and loans for the purposes of this act or for pay-
ing continuing costs of the annual administration of outstanding bonds.
125291.25. The proceeds of interim debt and bonds issued and
sold pursuant to this article shall be deposited in the State Treasury to
the credit of the California Stem Cell Research and Cures Fund, which
is hereby created in the State Treasury, except to the extent that proceeds
of the issuance of bonds are used directly to repay interim debt.
125291.30. Bonds in the total amount of three billion dollars
($3,000,000,000), not including the amount of any refunding bonds
issued in accordance with Section 125291.75, or as much thereof as is
necessary, may be issued and sold to provide a fund to be used for car-
rying out the purposes expressed in this article and to be used and sold
for carrying out the purposes of Section 125291.20 and to reimburse the
General Obligation Bond Expense Revolving Fund pursuant to 
Section 16724.5 of the Government Code. The bonds, when sold, shall be
and shall constitute a valid and binding obligation of the State of
California, and the full faith and credit of the State of California is here-
by pledged for the punctual payment of both the principal of, and inter-
est on, the bonds as the principal and interest become due and payable.
125291.35. The bonds authorized by this article shall be prepared,
executed, issued, sold, paid, and redeemed as provided in the State
General Obligation Bond Law (Chapter 4 (commencing with Section
16720) of Part 3 of Division 4 of Title 2 of the Government Code), and
all of the provisions of that law except Section 16727 apply to the bonds
and to this article and are hereby incorporated in this article as though
set forth in full in this article.
125291.40. (a) Solely for the purpose of authorizing the issuance
and sale, pursuant to the State General Obligation Bond Law, of the
bonds and interim debt authorized by this article, the California Stem
Cell Research and Cures Finance Committee is hereby created. For pur-
poses of this article, the California Stem Cell Research and Cures
Finance Committee is “the committee” as that term is used in the State
General Obligation Bond Law. The committee consists of the Treasurer,
the Controller, the Director of Finance, the Chairperson of the
California Institute for Regenerative Medicine, and two other members
of the Independent Citizens Oversight Committee (as created by the act)
chosen by the Chairperson of the California Institute for Regenerative
Medicine, or their designated representatives. The Treasurer shall serve
as chairperson of the committee. A majority of the committee may act
for the committee.
(b) For purposes of the State General Obligation Bond Law, 
the California Institute for Regenerative Medicine is designated 
the “board.”
125291.45. (a) The committee shall determine whether or not it is
necessary or desirable to issue bonds authorized pursuant to this arti-
cle in order to carry out the actions specified in this article and, if so,
the amount of bonds to be issued and sold. Successive issues of bonds
may be authorized and sold to carry out those actions progressively, and
it is not necessary that all of the bonds authorized to be issued be sold
at any one time. The bonds may bear interest which is includable in
gross income for federal income tax purposes if the committee deter-
mines that such treatment is necessary in order to provide funds for the
purposes of the act.
(b) The total amount of the bonds authorized by Section 125291.30
which may be issued in any calendar year, commencing in 2005, shall
not exceed three hundred fifty million dollars ($350,000,000). If less
than this amount of bonds is issued in any year, the remaining permit-
ted amount may be carried over to one or more subsequent years.
(c) An interest-only floating rate bond structure will be implement-
ed for interim debt and bonds until at least December 31 of the fifth full
calendar year after this article takes effect, with all interest to be paid
from proceeds from the sale of interim debt or bonds, to minimize debt
service payable from the General Fund during the initial period of basic
research and therapy development, if the committee determines, with the
advice of the Treasurer, that this structure will result in the lowest
achievable borrowing costs for the state during that five-year period
considering the objective of avoiding any bond debt service payments,
by the General Fund, during that period. Upon such initial determina-
tion, the committee may delegate, by resolution, to the Treasurer such
authority in connection with issuance of bonds as it may determine,
including, but not limited to, the authority to implement and continue
this bond financing structure (including during any time following the
initial five-year period) and to determine that an alternate financing
plan would result in significant lower borrowing costs for the state con-
sistent with the objectives related to the General Fund and to implement
such alternate financing plan.
125291.50. There shall be collected each year and in the same
manner and at the same time as other state revenue is collected, in addi-
tion to the ordinary revenues of the state, a sum in an amount required
to pay the principal of, and interest on, the bonds maturing each year.
It is the duty of all officers charged by law with any duty in regard to the
collection of the revenue to do and perform each and every act that is
necessary to collect that additional sum.
125291.55. Notwithstanding Section 13340 of the Government
Code, there is hereby appropriated from the General Fund in the State
Treasury, for the purposes of this article, an amount that will equal the
total of the following:
(a) The sum annually necessary to pay the principal of, and interest
on, bonds issued and sold pursuant to this article, as the principal and
interest become due and payable.
(b) The sum necessary to carry out Section 125291.60 appropriated
without regard to fiscal years.
125291.60. The Director of Finance may authorize the withdrawal
from the General Fund of an amount or amounts, not to exceed the
amount of the unsold bonds that have been authorized by the commit-
tee, to be sold for the purpose of carrying out this article. Any amount
withdrawn shall be deposited in the fund. Any money made available
under this section shall be returned to the General Fund, plus an
amount equal to the interest that the money would have earned in the
Pooled Money Investment Account, from money received from the sale
of bonds for the purpose of carrying out this article.
125291.65. The institute may request the Pooled Money Investment
Board to make a loan from the Pooled Money Investment Account in
accordance with Section 16312 of the Government Code for the purpos-
es of carrying out this article. The amount of the request shall not
exceed the amount of the unsold bonds that the committee, by resolu-
tion, has authorized to be sold for the purpose of carrying out this arti-
cle. The institute shall execute any documents required by the Pooled
Money Investment Board to obtain and repay the loan. Any amounts
loaned shall be deposited in the fund to be allocated by the institute in
accordance with this article.
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125291.70. All money deposited in the fund that is derived from
premium and accrued interest on bonds sold shall be reserved in the
fund and shall be available for transfer to the General Fund as a cred-
it to expenditures for bond interest.
125291.75. The bonds may be refunded in accordance with 
Article 6 (commencing with Section 16780) of Chapter 4 of Part 3 of
Division 4 of Title 2 of the Government Code, which is a part of the State
General Obligation Bond Law. Approval by the voters of the state for
the issuance of the bonds described in this article includes the approval
of the issuance of any bonds issued to refund any bonds originally
issued under this article or any previously issued refunding bonds.
125291.80. Notwithstanding any provision of this article or the
State General Obligation Bond Law, if the Treasurer sells bonds pur-
suant to this article that include a bond counsel opinion to the effect
that the interest on the bonds is excluded from gross income for federal
tax purposes, subject to designated conditions, the Treasurer may main-
tain separate accounts for the investment of bond proceeds and the
investment earnings on those proceeds. The Treasurer may use or direct
the use of those proceeds or earnings to pay any rebate, penalty, or
other payment required under federal law or to take any other action
with respect to the investment and use of bond proceeds required or
desirable under federal law to maintain the tax-exempt status of those
bonds and to obtain any other advantage under federal law on behalf
of the funds of this state.
125291.85. Inasmuch as the proceeds from the sale of bonds
authorized by this article are not “proceeds of taxes” as that term 
is used in Article XIII B of the California Constitution, the disburse-
ment of these proceeds is not subject to the limitations imposed by
that article.
Article 3. Definitions
125292.10. As used in this chapter and in Article XXXV of the
California Constitution, the following terms have the following mean-
ings:
(a) “Act” means the California Stem Cell Research and Cures Bond
Act constituting Chapter 3 (commencing with Section 125290.10) of
Part 5 of Division 106 of the Health and Safety Code.
(b) “Adult stem cell” means an undifferentiated cell found in a dif-
ferentiated tissue in an adult organism that can renew itself and may,
with certain limitations, differentiate to yield all the specialized cell
types of the tissue from which it originated.
(c) “Capitalized interest” means interest funded by bond proceeds.
(d) “Committee” means the California Stem Cell Research and
Cures Finance Committee created pursuant to subdivision (a) of
Section 125291.40.
(e) “Constitutional officers” means the Governor, Lieutenant
Governor, Treasurer, and Controller of California.
(f) “Facilities” means buildings, building leases, or capital 
equipment.
(g) “Floating-rate bonds” means bonds which do not bear a fixed
rate of interest until their final maturity date, including commercial
paper notes.
(h) “Fund” means the California Stem Cell Research and Disease
Cures Fund created pursuant to Section 125291.25.
(i) “Grant” means a grant, loan, or guarantee.
(j) “Grantee” means a recipient of a grant from the institute. All
University of California grantee institutions shall be considered as sep-
arate and individual grantee institutions.
(k) “Human reproductive cloning” means the practice of creating
or attempting to create a human being by transferring the nucleus from
a human cell into an egg cell from which the nucleus has been removed
for the purpose of implanting the resulting product in a uterus to 
initiate a pregnancy.
(l) “Indirect costs” mean the recipient’s costs in the administra-
tion, accounting, general overhead, and general support costs for
implementing a grant or loan of the institute. NIH definitions of indi-
rect costs will be utilized as one of the bases by the Scientific and
Medical Research Standards Working Group to create a guideline for
recipients on this definition, with modifications to reflect guidance by
the ICOC and this act.
(m) “Institute” means the California Institute for Regenerative
Medicine.
(n) “Interim standards” means temporary standards that perform
the same function as “emergency regulations” under the Administrative
Procedure Act (Government Code, Title 2, Division 3, Part 1, Chapter
4.5, Sections 11371 et seq.) except that in order to provide greater
opportunity for public comment on the permanent regulations, remain
in force for 270 days rather than 180 days.
(o) “Life science commercial entity” means a firm or organization,
headquartered in California, whose business model includes biomed-
ical or biotechnology product development and commercialization.
(p) “Medical ethicist” means an individual with advanced training
in ethics who holds a Ph.D., MA, or equivalent training and who spends
or has spent substantial time (1) researching and writing on ethical
issues related to medicine, and (2) administering ethical safeguards
during the clinical trial process, particularly through service on institu-
tional review boards.
(q) “Pluripotent cells” means cells that are capable of self-renew-
al, and have broad potential to differentiate into multiple adult cell
types. Pluripotent stem cells may be derived from somatic cell nuclear
transfer or from surplus products of in vitro fertilization treatments
when such products are donated under appropriate informed consent
procedures. These excess cells from in vitro fertilization treatments
would otherwise be intended to be discarded if not utilized for medical
research.
(r) “Progenitor cells” means multipotent or precursor cells that are
partially differentiated but retain the ability to divide and give rise to
differentiated cells.
(s) “Quorum” means at least 65 percent of the members who are
eligible to vote.
(t) “Research donor” means a human who donates biological 
materials for research purposes after full disclosure and consent.
(u) “Research funding” includes interdisciplinary scientific and
medical funding for basic research, therapy development, and the
development of pharmacologies and treatments through clinical tri-
als. When a facility’s grant or loan has not been provided to house all
elements of the research, therapy development, and/or clinical trials,
research funding shall include an allowance for a market lease rate of
reimbursement for the facility. In all cases, operating costs of the
facility, including, but not limited to, library and communication serv-
ices, utilities, maintenance, janitorial, and security, shall be included
as direct research funding costs. Legal costs of the institute incurred
in order to negotiate standards with federal and state governments
and research institutions; to implement standards or regulations; to
resolve disputes; and/or to carry out all other actions necessary to
defend and/or advance the institute’s mission shall be considered
direct research funding costs.
(v) “Research participant” means a human enrolled with full dis-
closure and consent, and participating in clinical trials.
(w) “Revenue positive” means all state tax revenues generated
directly and indirectly by the research and facilities of the institute are
greater than the debt service on the state bonds actually paid by the
General Fund in the same year.
(x) “Stem cells” mean nonspecialized cells that have the capacity to
divide in culture and to differentiate into more mature cells with spe-
cialized functions.
(y) “Vital research opportunity” means scientific and medical
research and technologies and/or any stem cell research not actual-
ly funded by the institute under subparagraph (C) of paragraph 
(1) of subdivision (c) of Section 125290.60 which provides a sub-
stantially superior research opportunity vital to advance medical
science as determined by at least a two-thirds vote of a quorum of
the members of the Scientific and Medical Research Funding
Working Group and recommended as such by that working group to
the ICOC. Human reproductive cloning shall not be a vital research
opportunity.
SEC. 6. Section 20069 of the Government Code is amended to
read:
(a) “State service” means service rendered as an employee or offi-
cer (employed, appointed or elected) of the state, the California
Institute for Regenerative Medicine and the officers and employees of
its governing body, the university, a school employer, or a contracting
agency, for compensation, and only while he or she is receiving com-
pensation from that employer therefor, except as provided in Article 4
(commencing with Section 20990) of Chapter 11.
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(b) “State service,” solely for purposes of qualification for benefits
and retirement allowances under this system, shall also include service
rendered as an officer or employee of a county if the salary for the serv-
ice constitutes compensation earnable by a member of this system
under Section 20638.
SEC. 7. Severability
If any provision of this act, or part thereof, is for any reason held 
to be invalid or unconstitutional, the remaining provisions shall not 
be affected, but shall remain in full force and effect, and to this end the
provisions of this act are severable.
SEC. 8. Amendments
The statutory provisions of this measure, except the bond provi-
sions, may be amended to enhance the ability of the institute to further
the purposes of the grant and loan programs created by the measure, by
a bill introduced and passed no earlier than the third full calendar year
following adoption, by 70 percent of the membership of both houses of
the Legislature and signed by the Governor, provided that at least 
14 days prior to passage in each house, copies of the bill in final form
shall be made available by the clerk of each house to the public and
news media.
Proposition 72
This law proposed by Senate Bill 2 of the 2003–2004 Regular
Session (Chapter 673, Statutes of 2003) is submitted to the people as a
referendum in accordance with the provisions of Section 9 of Article II
of the California Constitution.
This proposed law amends and adds sections to various codes; there-
fore, new provisions proposed to be added are printed in italic type to
indicate that they are new.
PROPOSED LAW
SECTION 1. The Legislature finds and declares all of the 
following: 
(a) The Legislature finds and declares that working Californians and
their families should have health insurance coverage. 
(b) The Legislature further finds and declares that most working
Californians obtain their health insurance coverage through their
employment. 
(c) The Legislature finds and declares that in 2001, more than
6,000,000 Californians lacked health insurance coverage at some time
and 3,600,000 Californians had no health insurance coverage at any
time. 
(d) The Legislature finds and declares that more than 80 percent 
of Californians without health insurance coverage are working people
or their families. Most of these working Californians without 
health insurance coverage work for employers who do not offer health
benefits. 
(e) The Legislature finds and declares that employment-based health
insurance coverage provides access for millions of Californians to the
latest advances in medical science, including diagnostic 
procedures, surgical interventions, and pharmaceutical therapies. 
(f) The Legislature finds and declares that people who are covered
by health insurance have better health outcomes than those who lack
coverage. Persons without health insurance are more likely to be in poor
health, more likely to have missed needed medications and treatment,
and more likely to have chronic conditions that are not properly 
managed. 
(g) The Legislature finds and declares that persons without health
insurance are at risk of financial ruin and that medical debt is the sec-
ond most common cause of personal bankruptcy in the United States. 
(h) The Legislature further finds and declares that the State of
California provides health insurance to low- and moderate-income
working parents and their children through the Medi-Cal and Healthy
Families programs and pays the cost of coverage for those working peo-
ple who are not provided health coverage through employment. The
Legislature further finds and declares that the State of California and
local governments fund county hospitals and clinics, community clin-
ics, and other safety net providers that provide care to those working
people whose employers fail to provide affordable health coverage to
workers and their families as well as to other uninsured persons. 
(i) The Legislature further finds and declares that controlling health
care costs can be more readily achieved if a greater share of working
people and their families have health benefits so that cost shifting is
minimized. 
(j) The Legislature finds and declares that the social and economic
burden created by the lack of health coverage for some workers and
their dependents creates a burden on other employers, the State of
California, affected workers, and the families of affected workers who
suffer ill health and risk financial ruin.
(k) It is therefore the intent of the Legislature to assure that working
Californians and their families have health benefits and that employers
pay a user fee to the State of California so that the state may serve as a
purchasing agent to pool those fees to purchase coverage for all work-
ing Californians and their families that is not tied to employment with
an individual employer. However, consistent with this act, if the employ-
er voluntarily provides proof of health care coverage, that employer is to
be exempted from payment of the fee.
(l) It is further the intent of the Legislature that workers who work
on a seasonal basis, for multiple employers, or who work multiple jobs
for the same employer should be afforded the opportunity to have health
coverage in the same manner as those who work full-time for a single
employer. 
(m) The Legislature recognizes the vital role played by the health
care safety net and the potential impact this act may have on the
resources available to county hospital systems and clinics, including
physicians or networks of physicians that refer patients to such hospitals
and clinics, as well as community clinics and other safety net providers.
It is the intent of the Legislature to preserve the viability of this impor-
tant health care resource. 
(n) Nothing in this act shall be construed to diminish or otherwise
change existing protections in law for persons eligible for public pro-
grams including, but not limited to, Medi-Cal, Healthy Families,
California Children’s Services, Genetically Handicapped Persons
Program, county mental health programs, programs administered by the
Department of Alcohol and Drug Programs, or programs administered
by local education agencies. It is further the intent of the Legislature to
preserve benefits available to the recipients of these programs, includ-
ing dental, vision, and mental health benefits. 
SEC. 2. Part 8.7 (commencing with Section 2120) is added to
Division 2 of the Labor Code, to read: 
PART 8.7. EMPLOYEE HEALTH INSURANCE 
CHAPTER 1. TITLE AND PURPOSE
2120. This part shall be known and may be cited as the Health
Insurance Act of 2003.
2120.1. (a) Large employers, as defined in Section 2122.3, shall
comply with the provisions of this part applicable to large employers
commencing on January 1, 2006.
(b) Medium employers, as defined in Section 2122.4, shall comply
with the provisions of this part applicable to medium employers com-
mencing on January 1, 2007, except that those employers with at least
20 employees but no more than 49 employees are not required to com-
ply with the provisions of this part unless a tax credit is enacted that is
available to those employers with at least 20 employees but no more
than 49 employees. The tax credit shall be 20 percent of net cost to 
the employer of the fee owed under Chapter 4 (commencing with
Section 2140). “Net cost” means the dollar amount of the employer fee
or the credit consistent with Section 2160.1 reduced by the employee
share of that fee or credit and further reduced by the value of state and
federal tax deductions.
2120.2. It is the purpose of this part to ensure that working
Californians and their families are provided health care coverage. 
2120.3. This part shall not be construed to diminish any protection
already provided pursuant to collective bargaining agreements or
employer-sponsored plans that are more favorable to the employees
than the health care coverage required by this part. 
